TScan Therapeutics announced the departure of CFO Jason A. Amello and CMO Chrystal Louis as part of a strategic reorganization. Separation agreements signed on September 24-25, 2026, terminate employment by November 1 or upon new engagement, with continued salary and benefits during notice periods. Amello receives an $85,000 milestone-based cash award under the November 2025 retention program, while Louis is entitled to a $125,000 similar award. Both executives retain previously disclosed termination-related payments. TScan Therapeutics operates in the biotechnology industry, developing immunotherapies for cancer treatment.
